Systemic sclerosis: pathogenic mechanisms and their implications for treatment
Seminars in Immunopathology · 2025-12 · 47 (1)
DOI: 10.1007/s00281-025-01065-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Immunopathology, online erschienen am 11.11.2025. Verfasst von Alain Lescoat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, EHESP, Irset -Institut de Recherche en Santé, Environnement Et Travail-UMRS, University of Rennes CHU Rennes, Rennes, France. alain.lescoat@c…. Hauptthemen laut MEDLINE: Scleroderma, Systemic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: NIH HHS.
Abstract (Originalsprache)
Systemic sclerosis (SSc) is a rare systemic autoimmune disease characterized by a triad of pathogenic mechanisms, including: a) microvascular hyperreactivity secondary to endothelial dysfunction, b) dysregulated immune activation of both innate and adaptive immunity, with the production of autoantibodies targeting nuclear antigens (e.g., anticentromere antibodies, anti-RNA polymerase III antibodies, and anti-topoisomerase I antibodies), and c) fibrosis of the skin and internal organs, such as the lungs, due to excessive extracellular matrix deposits produced by dysregulated myofibroblasts. Skin involvement plays a crucial role in the detrimental impact of SSc on quality of life. Skin fibrosis in SSc is characterized by the progressive accumulation of extracellular matrix components, including collagen, in the dermis, and is associated with adipocyte atrophy in the hypodermis. Visceral manifestations include fibrotic interstitial lung disease (ILD), myocardial involvement, pulmonary arterial hypertension, gastrointestinal manifestations, and scleroderma renal crisis. These manifestations are key determinants of prognosis and significant contributors to mortality in SSc. This review will explore the clinical features of SSc, the existing subtypes based on different classification approaches (such as skin-driven classifications, autoantibodies, or molecular subsets), epidemiology, identified etiologies, pathogenesis, current standards of care, and a selection of potential therapeutic perspectives. This review will emphasize SSc-related skin manifestations, including their pathogenesis and treatment, while also discussing other organ manifestations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inserm, EHESP, Irset -Institut de Recherche en Santé, Environnement Et Travail-UMRS, University of Rennes CHU Rennes, Rennes, France. alain.lescoat@chu-rennes.fr.
- Department of Internal Medicine and Clinical Immunology, CHU Rennes, South Hospital, 16 Bvd de Bulgarie, 35203 RENNES Cedex 2, BP 90347, Rennes, France. alain.lescoat@chu-rennes.fr.
- Scleroderma Program, University of Michigan, Ann Arbor, USA. alain.lescoat@chu-rennes.fr.
- Inserm, EHESP, Irset -Institut de Recherche en Santé, Environnement Et Travail-UMRS, University of Rennes CHU Rennes, Rennes, France.
- Dept. of Internal Medicine, Department of Dermatology, University of Michigan, Ann Arbor, MI, USA.
- Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, USA.
ORCID-Profile: Alain Lescoat
Förderung
- NIH HHS
Zitieren
APA
Lescoat, A., Lecureur, V., Gudjonsson, J. E., & Khanna, D. (2025). Systemic sclerosis: pathogenic mechanisms and their implications for treatment. Seminars in Immunopathology, 47(1). https://doi.org/10.1007/s00281-025-01065-6
Vancouver
Lescoat A, Lecureur V, Gudjonsson JE, Khanna D. Systemic sclerosis: pathogenic mechanisms and their implications for treatment. Seminars in Immunopathology. 2025;47(1). doi:10.1007/s00281-025-01065-6
BibTeX
@article{Lescoat2025,
author = {Lescoat, Alain and Lecureur, Valérie and Gudjonsson, Johann E and Khanna, Dinesh},
title = {Systemic sclerosis: pathogenic mechanisms and their implications for treatment},
journal = {Seminars in Immunopathology},
year = {2025},
volume = {47},
number = {1},
doi = {10.1007/s00281-025-01065-6}
}
EUVIMED